Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Entera Bio Ltd. - Ordinary Shares (NQ:ENTX)

3.190 UNCHANGED
Streaming Delayed Price Updated: 4:00 PM EDT, Aug 26, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 0
Open 3.190
Bid (Size) 2.910 (400)
Ask (Size) 3.950 (400)
Prev. Close 3.190
Today's Range 3.190 - 3.190
52wk Range 0.9100 - 4.200
Shares Outstanding 28,804,411
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
News headline image
Entera Appoints Global Pharmaceutical Leader Riccardo Paolo Camisasca, M.D., as Chief Medical Officer Ahead of Planned EB613 Phase 3 Initiation
From Entera Bio Ltd.
Via GlobeNewswire
News headline image
Entera Bio Eyes Phase 3 Start for Oral Osteoporosis Drug EB613 After FDA Agreement ↗
Entera Bio (NASDAQ:ENTX) plans to begin a Phase 3 study of its oral osteoporosis candidate EB613 after reaching agreement with the U.S. Food and Drug Administration on a 12-month, placebo-controlled... 
Via MarketBeat

Performance

YTD
+80.2%
+80.2%
1 Month
-18.6%
-18.6%
3 Month
+168.1%
+168.1%
6 Month
+101.9%
+101.9%
1 Year
+61.1%
+61.1%

More News

Read More
Entera Bio (NASDAQ:ENTX) Slides on Wider Q2 Loss Despite FDA Phase 3 Alignment and $275M Cash Raise ↗
Via Chartmill
News headline image
Entera Announces Second Quarter 2026 Financial Results and Business Updates
From Entera Bio Ltd.
Via GlobeNewswire
News headline image
Entera Bio Phase 2 Data Supporting EB613’s (Oral PTH(1-34)) Anabolic Effect on Postmenopausal Women with Osteoporosis at High Risk for Fracture Selected for Plenary Poster Session Presentation at the ASBMR 2026 Annual Meeting
From Entera Bio Ltd.
Via GlobeNewswire
News headline image
Entera Bio to Participate in the Canaccord Genuity 46th Annual Growth Conference
From Entera Bio Ltd.
Via GlobeNewswire
Which stocks are moving on Monday? ↗
Via Chartmill
Curious about the most active stocks on Monday? ↗
Via Chartmill
News headline image
12 Health Care Stocks Moving In Monday's Intraday Session ↗
Via Benzinga
Monday's session: top gainers and losers ↗
Via Chartmill
Let's uncover which stocks are experiencing notable gaps during today's session. ↗
Via Chartmill
News headline image
Entera Bio Announces Pricing of Oversubscribed $275 Million Private Placement
From Entera Bio Ltd.
Via GlobeNewswire
What's going on in today's after hours session ↗
Via Chartmill
Top movers analysis one hour before the close of the markets on 2026-06-22: top gainers and losers in today's session. ↗
Via Chartmill
News headline image
Entera Bio Receives Positive FDA Feedback on 12-Month Registrational Phase 3 Study for EB613 - the First Oral Anabolic Tablet in Development for Postmenopausal Women with Osteoporosis
From Entera Bio Ltd.
Via GlobeNewswire
News headline image
Entera Reports Robust Preclinical Data for EB612 (Oral LA-PTH(1-34)) for Hypoparathyroidism and EB618 (Oral GLP-1/Glucagon) for Obesity at ENDO 2026
From Entera Bio Ltd.
Via GlobeNewswire
News headline image
ENDO 2026 Oral Presentation Highlights Comparative Clinical Data for Entera’s Breakthrough Single Tablet EB613 (First-in-Class Oral PTH(1-34) Anabolic for Osteoporosis)
From Entera Bio Ltd.
Via GlobeNewswire
News headline image
Entera’s EB613, First-in-Class Oral PTH(1-34) Anabolic for Osteoporosis - Single Tablet Data Selected for Late Breaking Oral Presentation at ENDO 2026 Annual Meeting; Additional Oral Peptide Pipeline Data Accepted for Presentation
From Entera Bio Ltd.
Via GlobeNewswire
Get insights into the top gainers and losers of Friday's after-hours session. ↗
Via Chartmill
News headline image
Entera Announces First Quarter 2026 Financial Results and Updates Across its Oral Peptide Programs
From Entera Bio Ltd.
Via GlobeNewswire
News headline image
Entera Bio to Host Key Opinion Leader Webinar Highlighting the Osteoporosis Treatment Landscape and the Opportunity for EB613
From Entera Bio Ltd.
Via GlobeNewswire
News headline image
Entera Bio Announces Pricing of $10.0 Million Direct Investment by BVF Partners with Potential for up to $24.5 Million in Total Proceeds
From Entera Bio Ltd.
Via GlobeNewswire
News headline image
ENTX Rallies As Insiders Buy Company Shares — Retail Hopes For ‘Exciting Days’ Ahead ↗
Via Stocktwits
Big Pharma Just Put Peptides Back on the Map – Which Players Are Still Under the Radar?
Via AB Newswire
News headline image
12 Health Care Stocks Moving In Wednesday's Pre-Market Session ↗
Via Benzinga

Frequently Asked Questions

Is Entera Bio Ltd. - Ordinary Shares publicly traded?
Yes, Entera Bio Ltd. - Ordinary Shares is publicly traded.
What exchange does Entera Bio Ltd. - Ordinary Shares trade on?
Entera Bio Ltd. - Ordinary Shares trades on the Nasdaq Stock Market
What is the ticker symbol for Entera Bio Ltd. - Ordinary Shares?
The ticker symbol for Entera Bio Ltd. - Ordinary Shares is ENTX on the Nasdaq Stock Market
What is the current price of Entera Bio Ltd. - Ordinary Shares?
The current price of Entera Bio Ltd. - Ordinary Shares is 3.190
When was Entera Bio Ltd. - Ordinary Shares last traded?
The last trade of Entera Bio Ltd. - Ordinary Shares was at 08/26/26 04:00 PM ET
What is the market capitalization of Entera Bio Ltd. - Ordinary Shares?
The market capitalization of Entera Bio Ltd. - Ordinary Shares is 91.89M
How many shares of Entera Bio Ltd. - Ordinary Shares are outstanding?
Entera Bio Ltd. - Ordinary Shares has 92M shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.